Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers

Area of Science:

• Gynecologic Oncology
• Cancer Cell Biology
• Molecular Therapeutics

Background:

• Gynecologic cancers (ovarian, uterine, cervical) are significant causes of mortality, often driven by defective cell cycle regulation.
• The cell cycle's progression is tightly controlled by cyclin-dependent kinases (CDKs) and checkpoints that respond to DNA damage.
• Aberrant CDK activity and checkpoint failures promote uncontrolled proliferation, fueling cancer development and progression.

Purpose of the Study:

• To review the fundamental principles of the cell cycle and its regulation in cancer.
• To elucidate the mechanistic link between CDKs and homologous recombination (HR) DNA repair.
• To explore the therapeutic potential of CDK inhibitors in gynecologic malignancies.

Main Methods:

• Review of mechanistic studies on cell cycle regulation and DNA repair.
• Analysis of the role of CDKs in homologous recombination (HR) repair.
• Overview of preclinical and clinical data on small molecule CDK inhibitors.

Main Results:

• CDK activity is essential for both cell cycle progression and homologous recombination (HR) DNA repair.
• Pharmacological CDK inhibition presents a synthetic lethal strategy when combined with DNA damaging agents.
• CDK inhibitors show promise in combination therapies for gynecologic cancers.

Conclusions:

• Targeting CDKs offers a promising strategy to enhance the efficacy of existing treatments for gynecologic cancers.
• The interplay between CDKs and HR repair provides a rationale for combining CDK inhibitors with PARP inhibitors and other DNA damaging therapies.
• Further development of CDK inhibitors and combination strategies is warranted to improve patient outcomes in gynecologic malignancies.